Newland: Signed a cooperation agreement for GLP-1 class long-acting peptide innovative drugs

Newland announced that the company recently signed a cooperation development and licensing agreement with Nanjing Zhihe Pharmaceutical Technology Co., Ltd. The two parties will carry out strategic cooperation in the field of GLP-1 class long-acting peptide innovative drugs. The cooperation includes drug research and development, production, commercialization, and external transactions. The signing of this agreement does not constitute a related party transaction, nor does it constitute a major asset restructuring, and it does not meet the review standards of the company's board of directors and shareholders' meeting. The agreement does not involve specific amounts and will not have a significant impact on the company's financial status, operating results, and performance for this year